PMVK Activators
Phosphomevalonate Kinase (PMVK) is a protein encoded by the PMVK gene in humans. It plays a vital role in isoprenoid and sterol synthesis as part of the mevalonate pathway, a crucial metabolic pathway involved in a variety of cellular processes.PMVK catalyzes the phosphorylation of mevalonate-5-phosphate into mevalonate-5-diphosphate, representing the third step in the mevalonate pathway. This pathway is responsible for the synthesis of isoprenoids, a diverse class of compounds that includes cholesterol, dolichols, ubiquinones, and isopentenyl tRNA, all of which are essential for various cellular functions.
Cholesterol, for example, is a major component of cell membranes and a precursor for the synthesis of steroid hormones and bile acids. Dolichols play a role in protein glycosylation, while ubiquinones participate in electron transport in mitochondria, and isopentenyl tRNA is involved in protein synthesis.Given its important role in the mevalonate pathway, alterations in PMVK function could potentially impact a variety of cellular processes. Dysregulation of cholesterol synthesis, for instance, could lead to disorders such as hypercholesterolemia, potentially contributing to cardiovascular disease.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Farnesol | 4602-84-0 | sc-204748 sc-204748A | 50 ml 100 ml | $281.00 $374.00 | 2 | |
Farnesol, an intermediate in sterol biosynthesis, indirectly influences PMVK activity through feedback regulation in the mevalonate pathway. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin, a HMG-CoA reductase inhibitor, indirectly affects PMVK activity by modulating mevalonate pathway flux, potentially upregulating PMVK as a compensatory mechanism. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin, similar to Lovastatin, indirectly influences PMVK activity by altering mevalonate pathway dynamics, potentially leading to compensatory upregulation of PMVK. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin, another HMG-CoA reductase inhibitor, can indirectly modulate PMVK activity by affecting the overall flux in the mevalonate pathway. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin, also a HMG-CoA reductase inhibitor, potentially influences PMVK activity indirectly through pathway flux modulation in the mevalonate pathway. | ||||||
Pravastatin | 81093-37-0 | sc-222188 | 50 mg | $408.00 | 1 | |
Pravastatin, by inhibiting HMG-CoA reductase, indirectly affects PMVK activity, potentially leading to its upregulation as part of a compensatory mechanism in the mevalonate pathway. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin, similar to other statins, can indirectly modulate PMVK activity by impacting the mevalonate pathway and its associated regulatory mechanisms. | ||||||
Squalene | 111-02-4 | sc-281155 sc-281155A sc-281155B | 10 ml 100 ml 500 ml | $49.00 $92.00 $215.00 | 1 | |
Squalene, an intermediate in cholesterol synthesis, may indirectly influence PMVK activity through regulatory feedback mechanisms in the mevalonate pathway. | ||||||